glp-1 non-diabetic weight loss effectiveness Patients on Medications Have an Increased Likelihood of GI Side Effects Compared to Patients on Other Medications Is GLP-1 the Same as
Description
26 They are generally mild, nondisabling, and most frequently occur within the first 26 weeks of treatment
Chronic Disease Management: Increased use of GLP-1 medications may reduce the incidence of diabetes-related hospitalizations by 10%15% and cardiovascular events by up to 20%, improving long-term population health outcomes
Use of incretin-based therapies in women using hormone replacement therapy (HRT)
Patients should report new symptoms such as fatigue, cold intolerance, hair loss, irregular heartbeat, or tremor to their provider promptly
